Radionuclide production for therapeutic radiopharmaceuticals

Appl Radiat Isot. 2002 Nov;57(5):657-64. doi: 10.1016/s0969-8043(02)00180-x.


A fundamental task within the framework of a project searching for new radiopharmaceuticals for systemic therapy was the evaluation of the capabilities of the Portuguese Research Reactor (RPI) for the production of several important radionuclides. The feasibility of producing 64Cu, 77As, 153Sm, 165Dy, 166Ho, 170Tm, 177Lu, 186Re, 199Au and 111Ag in useful quantities was evaluated for the present RPI operation schedule (12 h cycles) and for continuous operation. The main evaluation criteria are expressed in terms of specific activity for continuous irradiation and/or 12 h cycle and the use of natural or enriched targets if necessary. Selected samples were irradiated and a comparison between measured activities and values calculated according to the irradiation schedule and using the same software was performed.

MeSH terms

  • Beta Particles / therapeutic use
  • Copper / radiation effects
  • Fast Neutrons
  • Holmium / radiation effects
  • Humans
  • Radiochemistry
  • Radioisotopes / isolation & purification*
  • Radioisotopes / therapeutic use*
  • Radiopharmaceuticals / isolation & purification*
  • Radiopharmaceuticals / therapeutic use*
  • Rhenium / radiation effects
  • Samarium / radiation effects


  • Radioisotopes
  • Radiopharmaceuticals
  • Samarium
  • Rhenium
  • Copper
  • Holmium